What's up at stealthy Cal­i­co Labs? AI star Daphne Koller makes an abrupt ex­it as top team shrinks

8 years ago
People
AI

Bio­gen, Ab­b­Vie yank MS drug Zin­bry­ta off the mar­ket in the wake of en­cephali­tis cas­es

8 years ago
R&D

Roche, Io­n­is her­ald a big win in ear­ly-stage Hunt­ing­ton’s dis­ease tri­al, demon­strate dis­ease mod­i­fy­ing po­ten­tial

8 years ago
R&D

With Resta­sis in its crosshairs, My­lan adds a Botox biosim with Re­vance; Ver­tex starts sec­ond PhI­II triple com­bo CF ...

8 years ago
News Briefing

Watch out En­do: Sor­ren­to is af­ter your $1B+ drug with FDA OK of ZTli­do

8 years ago
Pharma

No­var­tis wants to be a leader in a new gen­er­a­tion of pre­scrip­tion dig­i­tal med pro­grams, pairs with Pear

8 years ago
R&D
Pharma

It’s of­fi­cial: EMA to move in­to per­ma­nent Am­s­ter­dam premis­es in No­vem­ber ‘19 amid con­tin­ued protests from Italy

8 years ago
Pharma

Take­da-part­nered Finch Ther­a­peu­tics grabs $36M and looks to leapfrog the pack in mi­cro­bio­me R&D

8 years ago
Financing

PureTech's Gele­sis brings in $30M to back its FDA pitch on a new weight loss ther­a­py with trou­ble­some da­ta

8 years ago
Financing

Suck­ing up tal­ent out of No­var­tis, a boom­ing Ru­bius adds an­oth­er $100 mil­lion mega-round to the kit­ty

8 years ago
Financing

Scopia snags two board seats at Acor­da fol­low­ing stock pur­chase; BeiGene nabs sec­ond in­di­ca­tion for Revlim­id in Chi­na

8 years ago
News Briefing

Sen­tenc­ing date loom­ing, a fed­er­al judge's rul­ing could leave Mar­tin Shkre­li in prison for years to come

8 years ago
People

On this Rare Dis­ease Day, let's all com­mit to help­ing rec­og­nize the life and work of biotech gi­ant Hen­ri A. Ter­meer

8 years ago
Biotech Voices

Armed with pub­lished an­i­mal da­ta, gene-edit­ing pi­o­neer In­tel­lia maps the road to an IND

8 years ago
Discovery

No­vo Hold­ings is look­ing for a few good su­per­bug biotechs in need of ear­ly-stage fund­ing — in­vest­ing $165M

8 years ago
Financing

Di­al­ing down the tox­ic ef­fects of ra­di­a­tion on can­cer pa­tients, Galera gets break­through sta­tus on Phase IIb da­ta

8 years ago
R&D

Start­up mak­ing Cas9 proxy for gene edit­ing gets $55M to de­vel­op tools/soft­ware

8 years ago
Financing

As­traZeneca spins out 6 drugs and an R&D group in­to Viela Bio, which emerges with a piv­otal pro­gram and $250M

8 years ago
Financing

Cel­gene shak­en again af­ter the FDA kicks back their mar­ket­ing ap­pli­ca­tion on block­buster hope­ful ozan­i­mod

8 years ago
R&D

Ex­elix­is/Dai­ichi Sankyo ask Japan­ese reg­u­la­tors for green light on hy­per­ten­sion drug; Bris­tol-My­ers Squibb li­cens­es ...

8 years ago
News Briefing

No­var­tis’ on­col­o­gy re­search chief in Chi­na jumps to up­start EpimAb in Shang­hai

8 years ago
People
China

J&J col­lab­o­rates with Aldeyra on new drugs for sys­temic in­flam­ma­to­ry dis­eases

8 years ago
R&D
Pharma

Dana-Far­ber’s Lau­rie Glim­ch­er helps launch a NYC biotech up­start with some key in­sights on im­muno-on­col­o­gy tech

8 years ago
Financing
Startups

Haul­ing in a $100M mega-round, gene ther­a­py start­up Gen­er­a­tion Bio builds al­ter­na­tive to po­ten­tial­ly risky vi­ral ...

8 years ago
Financing
Startups
First page Previous page 1062106310641065106610671068 Next page Last page
A service from the Financial Times